CLAIMS

1. The use of a Programmed Death (PD-1) antagonist in combination with activated T cells that specifically recognize a tumor antigen in the manufacture of a medicament for the treatment of tumor in a subject, wherein the tumor expresses the tumor antigen, and wherein the PD-1 antagonist is an antibody that specifically binds Programmed Death Ligand 1 (PD-L1), an anti-PD-LI antisense RNA, an antibody that specifically binds PD-1, or an anti-PD-1 antisense RNA, and wherein:

the antibody that specifically binds PD-1 is (1) a monoclonal antibody or an antigen binding fragment thereof, (2) a humanized antibody or an antigen binding fragment thereof, or (3) an immunoglobulin fusion protein;

the antibody that specifically binds PD-LI is (1) a monoclonal antibody or an antigen binding fragment thereof, (2) a humanized antibody or an antigen binding fragment thereof, or (3) an immunoglobulin fusion protein; and

the tumor is acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant myeloma, breast cancer, lung cancer, prostate cancer, colon cancer, melanoma or renal cell carcinoma (RCC).

2. The use of claim 1, wherein the PD-1 antagonist is the antibody that specifically binds PD-1 or the antibody that specifically binds PD-LI.

3. The use of claim 1, wherein the subject is immunosuppressed.

4. The use of claim 1, wherein the PD-1 antagonist is the anti-PD-1 antisense RNA or the anti-PD-LI antisense RNA.

5. The use of claim 2, wherein the PD-1 antagonist is the antibody that specifically binds PD-1.

6. The use of claim 2, wherein the PD-1 antagonist is the antibody that specifically binds PD-LI.

7. The use of any one of claims 1-6, wherein the tumor antigen is PRAME, WTl, Survivin, cyclin D, cyclin E, proteinase 3 and its peptide PRl, neutrophil elastase, cathepsin G, MAGE, MART, tyrosinase, GP100, NY-Eso-1, herceptin, carcino- embryonic antigen (CEA), or prostate specific antigen (PSA).

8. The use of any one of claims 1-7, wherein the subject is human.

9. The use of any one of claims 1-8, wherein the tumor is acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant myeloma, breast cancer, lung cancer, prostate cancer, colon cancer, or renal cell carcinoma (RCC).

10. The use of any one of claims 1-9, wherein the tumor is a malignant melanoma.

11. The use of any one of claims 1-10, wherein the T cells are CD4+ or CD8+ T cells.